Does brand + generic really add up? Sandoz, Actavis execs count the ways

Carly Helfand These days, companies are increasingly looking to put both branded and generic meds under one roof. And Peter Goldschmidt, the U.S. president of Novartis' Sandoz unit, ...

FDA demands new warnings on dermal fillers from Actavis, Galderma

Carly Helfand Dermal fillers are meant to minimize the appearance of wrinkles and give the face a smoother, fuller appearance. But they may also have some nasty consequences if injected ...

Valeant, Actavis on verge of FDA nods in IBS for Xifaxan, eluxadoline

Tracy Staton Get ready for a showdown in the irritable bowel syndrome market. FiercePharma News

Actavis talks to DOJ about resolving probe of Warner Chilcott marketing misdeeds

Eric Palmer Actavis is trying to rid itself of some nasty legal entanglements that it picked up in its $ 8.5 billion deal for Ireland's Warner Chilcott, meeting with the Justice ...

Actavis delivers big Q1 sales boost, thanks to Forest, Allergan buys

Emily Wasserman Spring is in the air, and Actavis is starting to see the fruits of last year's M&A. The company reported first-quarter earnings that beat expectations–and ...

Want Actavis? Prepare to pay up, CEO says

Carly Helfand Actavis CEO Brent Saunders expects pharma's deal wave to continue. But make no mistake, he says: Potential suitors are going to have to pony up a pretty penny if they ...

Actavis has an eye on more deals, for ‘couple billion dollars’ or so

Damian Garde Actavis, still awaiting the close of its $ 66 billion buyout of Allergan, is on the lookout for more bolt-on acquisitions. FierceBiotech News

Can Actavis deliver a promised $6B boost from this pipeline?

John Carroll FierceBiotech News

AstraZeneca continues its respiratory land grab with $600M-plus Actavis deal

Carly Helfand AstraZeneca CEO Pascal Soriot has said he wants to dominate in the respiratory field. Actavis CEO Brent Saunders has no such ambitions. Now, the two have struck a deal. FiercePharma ...

Actavis plan to stop making original Namenda derailed by court

Eric Palmer A federal judge in New York has decided Actavis CEO Brent Saunders' plan to move patients to a new version of its Alzheimer's treatment Namenda IR by stopping production ...

Actavis could make out big time with FDA’s knock to Mallinckrodt, Kudco drugs

Eric Palmer While the industry is fixated on whether Actavis will save Allergan from a hostile takeover by Valeant or whether Pfizer might be sizing up a run at Actavis, there was a ...

Actavis ready to thwart Valeant with $60B-plus Allergan buyout: Bloomberg

Carly Helfand Heads up, Valeant. Actavis is reportedly in talks to snatch up Allergan–and word is it could happen quickly. FiercePharma News
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS